Literature DB >> 28899614

Measuring pathology using the PANSS across diagnoses: Inconsistency of the positive symptom domain across schizophrenia, schizoaffective, and bipolar disorder.

Ariana E Anderson1, Maxwell Mansolf2, Steven P Reise2, Adam Savitz3, Giacomo Salvadore3, Qingqin Li3, Robert M Bilder4.   

Abstract

Although the Positive and Negative Syndrome Scale (PANSS) was developed for use in schizophrenia (SZ), antipsychotic drug trials use the PANSS to measure symptom change also for bipolar (BP) and schizoaffective (SA) disorder, extending beyond its original indications. If the dimensions measured by the PANSS are different across diagnoses, then the same score change for the same drug condition may have different meanings depending on which group is being studied. Here, we evaluated whether the factor structure in the PANSS was consistent across schizophrenia (n = 3647), bipolar disorder (n = 858), and schizoaffective disorder (n = 592). Along with congruency coefficients, Hancock's H, and Jaccard indices, we used target rotations and statistical tests of invariance based on confirmatory factor models. We found the five symptom dimensions measured by the 30-item PANSS did not generalize well to schizoaffective and bipolar disorders. A model based on an 18-item version of the PANSS generalized better across SZ and BP groups, but significant problems remained in generalizing some of the factors to the SA sample. Schizophrenia and bipolar disorder showed greater similarity in factor structure than did schizophrenia and schizoaffective disorder. The Anxiety/Depression factor was the most consistent across disorders, while the Positive factor was the least consistent.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antipsychotic; Anxiety; Clinical trials; Drug trials; Factor analyses; Factor structure; Negative symptoms

Mesh:

Year:  2017        PMID: 28899614      PMCID: PMC5681392          DOI: 10.1016/j.psychres.2017.08.009

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  31 in total

1.  Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials.

Authors:  Matthias J Müller; Armin Szegedi
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

2.  A RATIONALE AND TEST FOR THE NUMBER OF FACTORS IN FACTOR ANALYSIS.

Authors:  J L HORN
Journal:  Psychometrika       Date:  1965-06       Impact factor: 2.500

3.  A Study of the Comparability of External Criteria for Hierarchical Cluster Analysis.

Authors:  G W Milligan; M C Cooper
Journal:  Multivariate Behav Res       Date:  1986-10-01       Impact factor: 5.923

4.  Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

Authors:  Srihari Gopal; David W Hough; Haiyan Xu; Julia M Lull; Cristiana Gassmann-Mayer; Bart M Remmerie; Marielle H Eerdekens; David W Brown
Journal:  Int Clin Psychopharmacol       Date:  2010-09       Impact factor: 1.659

5.  Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

Authors:  Carla M Canuso; Nina Schooler; Jennifer Carothers; Ibrahim Turkoz; Colette Kosik-Gonzalez; Cynthia A Bossie; David Walling; Jean-Pierre Lindenmayer
Journal:  J Clin Psychopharmacol       Date:  2010-10       Impact factor: 3.153

6.  Negative symptoms and executive function in schizophrenia: does their relationship change with illness duration?

Authors:  Alexandra Bagney; Roberto Rodriguez-Jimenez; Isabel Martinez-Gras; Eva Maria Sanchez-Morla; Jose Luis Santos; Miguel Angel Jimenez-Arriero; Antonio Lobo; Patrick D McGorry; Tomas Palomo
Journal:  Psychopathology       Date:  2012-11-09       Impact factor: 1.944

7.  Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

Authors:  Michelle Kramer; Robert Litman; David Hough; Rosanne Lane; Pilar Lim; Yanning Liu; Mariëlle Eerdekens
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-27       Impact factor: 5.176

8.  Five factor model of schizophrenia: replication across samples.

Authors:  J P Lindenmayer; S Grochowski; R B Hyman
Journal:  Schizophr Res       Date:  1995-02       Impact factor: 4.939

9.  PANSS factors and scores in schizophrenic and bipolar disorders during an index acute episode: a further analysis of the cognitive component.

Authors:  E Daneluzzo; L Arduini; O Rinaldi; M Di Domenico; C Petruzzi; A Kalyvoka; A Rossi
Journal:  Schizophr Res       Date:  2002-07-01       Impact factor: 4.939

10.  Iteration of Partially Specified Target Matrices: Applications in Exploratory and Bayesian Confirmatory Factor Analysis.

Authors:  Tyler M Moore; Steven P Reise; Sarah Depaoli; Mark G Haviland
Journal:  Multivariate Behav Res       Date:  2015       Impact factor: 5.923

View more
  7 in total

1.  Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.

Authors:  Ariana E Anderson; Stephen Marder; Steven P Reise; Adam Savitz; Giacomo Salvadore; Dong Jing Fu; Qingqin Li; Ibrahim Turkoz; Carol Han; Robert M Bilder
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

2.  NKCC1 to KCC2 mRNA Ratio in Schizophrenia and Its Psychopathology: a Case-Control Study.

Authors:  Hoorie Mohaghghegh; Esmaeil Shahsavand Ananloo; Mahmoudreza Hadjighasem; Morteza Karimipour; Shiva Hashemizadeh; Seyyed Ali Ahmadi Abhari
Journal:  J Mol Neurosci       Date:  2022-05-27       Impact factor: 2.866

3.  Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model.

Authors:  Ariana E Anderson; Steven P Reise; Stephen R Marder; Maxwell Mansolf; Carol Han; Robert M Bilder
Journal:  Innov Clin Neurosci       Date:  2017-12-01

4.  The component structure of the scales for the assessment of positive and negative symptoms in first-episode psychosis and its dependence on variations in analytic methods.

Authors:  Marc S Tibber; James B Kirkbride; Eileen M Joyce; Stanley Mutsatsa; Isobel Harrison; Thomas R E Barnes; Vyv Huddy
Journal:  Psychiatry Res       Date:  2018-10-30       Impact factor: 3.222

5.  Handwriting movements for assessment of motor symptoms in schizophrenia spectrum disorders and bipolar disorder.

Authors:  Yasmina Crespo; Antonio Ibañez; María Felipa Soriano; Sergio Iglesias; Jose Ignacio Aznarte
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

6.  Generalizability of machine learning for classification of schizophrenia based on resting-state functional MRI data.

Authors:  Xin-Lu Cai; Dong-Jie Xie; Kristoffer H Madsen; Yong-Ming Wang; Sophie Alida Bögemann; Eric F C Cheung; Arne Møller; Raymond C K Chan
Journal:  Hum Brain Mapp       Date:  2019-10-01       Impact factor: 5.038

7.  Levels of circulating endothelial progenitor cells inversely correlate with manic and positive symptom severity in patients with bipolar disorder.

Authors:  Ying-Jay Liou; Mu-Hong Chen; Ju-Wei Hsu; Kai-Lin Huang; Po-Hsun Huang; Ya-Mei Bai
Journal:  Brain Behav       Date:  2022-04-28       Impact factor: 3.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.